Since 2017, a systemic therapy with brentuximab vedotin (BV)4, 5 has been approved for CD30‐positive cutaneous T cell lymphomas as second‐line therapy and shows high efficacy with acceptable tolerability in mycosis fungoides (MF), Sézary syndrome and CD30‐positive lymphoproliferations.6, 7. Here, TNFRSF8 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.